Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine

Psychopharmacology

Volumn 133, Issue 1, 1997, Pages 95-98

  Mihara, Kazuo ^a   Otani, Koichi ^a   Suzuki, Akihito ^a   Yasui, Norio ^a   Nakano, Hajime ^a   Meng, Xianmin ^a   Ohkubo, Tadashi ^a   Nagasaki, Takako ^b   Kaneko, Sunao ^a   Tsuchida, Shigeki ^a   Sugawara, Kazunobu ^a   Gonzalez, Frank J ^c  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Goshogawara City Hospital   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CYP2D6 genotype; m Chlorophenylpiperazine; Metabolism; Steady state plasma concentration; Trazodone

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CYTOCHROME P450 ISOENZYME; TRAZODONE;

ADULT; ALLELE; ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PIPERAZINES; SEROTONIN UPTAKE INHIBITORS; TRAZODONE;

EID: 9844262794     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050376     Document Type: Article

References (23)

1. Bertilsson L, Dahl ML (1996) Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 5:200-223
2. Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brochmeier D, Eichelbaum M (1994) The influcence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209-218
3. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558
4. Dahl ML, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjoqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51:12-17
5. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, Bertilsson L (1995) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capactiy in Korean, Japanese and Chinese subjects. Pharmacogenetics 5:159-164
6. Dahl ML, Bertilsson L, Nordin C (1996) Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology 123:315-319
7. Evert B, Griese EU, Eichelbaum M (1994) A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 350:434-439
8. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48:943-950
9. Heim M, Meyer UA (1990) Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532
10. Ishida M, Otani K, Kaneko S, Ohkubo T, Osanai T, Yasui N, Mihara K, Higuchi H, Sugawara K (1995) Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 10:143-146
11. Jauch R, Kopitar Z, Prox A, Zimmer A (1976) Pharmakokinetik und Stoffwechsel von Trazodone beim Menschen. Arzneimittelforschung 26:2084-2089
12. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjoqvist F, Ingelman-Simdberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829
13. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P450 locus: characterization of variant CYP2D6 genes present in subjects with diminished capactity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459
14. Mayol RF, Cole CA, Colson KE, Kerns EH (1994) Isolation and identification of the major urinary metabolite of m-chlorophenylpiperazine in the rat. Drug Metab Dispos 22:171-174
15. Monteleone P, Gnocchi G, Delrio G (1989) Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. J Clin Psychopharmacol 9:284-287
16. Ohkubo T, Osanai T, Sugawara K, Ishida M, Otani K, Mihara K, Yasui N (1995) High performance liquid chromatographic determination of trazodone and l-m-chlorophenylpiperazine with ultraviolet and electrochemical detector. J Pharm Pharmacol 47:340-344
17. Otani K, Yasui N, Kaneko S, Ishida M, Ohkubo T, Osanai T, Sugawara K, Fukushima Y (1995) Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol 10:115-117
18. Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T, Sugawara K (1996) Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther Drug Monit 18:164-167
19. Pirmohamed M, Allott R, Green VJ, Kitteringham NR, Chadwick D, Park BK (1994) Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. Br J Clin Pharmacol 37:577-581
20. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B (1994) Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 3:923-926
21. Spina E, Martines C, Caputi AP, Cabaleda J, Pinas B, Carrillo JA, Benitez J (1991) Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 41:467-470
22. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-223
23. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y (1995) Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 17:333-335